Development of new hormonal male contraception for the couple
Andrology · 2024-10 · 12 (7) · 1506-1511
DOI: 10.1111/andr.13654 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Andrology, online erschienen am 15.05.2024. Verfasst von Jeffrey M Kroopnick und 2 weiteren Autor:innen. Beteiligte Einrichtung: Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Contraceptive Agents, Male. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Current options for male contraception are limited to condoms, the withdrawal method, or a vasectomy. Studies indicate that men have expressed growing interest in bearing responsibility for family planning.
Objectives
To review prior studies investigating the role of an androgen‐only or androgen with progestin regimen for hormonal male contraception and to provide an update of a promising new hormonal agent, a transdermal gel.
Discussion
Thus far, there have been six studies conducted in couples evaluating the contraceptive efficacy of an androgen‐only or androgen co‐administered with a progestin regimen for hormonal male contraception. The only ongoing study is by the National Institute of Child Health and Human Development, in collaboration with the Population Council. They have developed a novel transdermal gel containing testosterone and segesterone acetate (Nestorone), a progestin. An ongoing phase II study enrolling more than 460 couples has shown great potential with respect to the product's efficacy, safety, reversibility, and acceptability. As this agent advances in development, a rapid at‐home test for sperm concentration will provide couples with immediate feedback regarding their potential for pregnancy.
Conclusion
There is promise for the first‐of‐its‐kind hormonal male contraceptive, a transdermal gel, to achieve market approval for distribution in the United States and elsewhere. Its safety, efficacy, reversibility, and user‐control are all appealing qualities that make it readily adoptable for clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
ORCID-Profile: Jeffrey M Kroopnick
Zitieren
APA
Kroopnick, J. M., Lee, M. S., & Blithe, D. L. (2024). Development of new hormonal male contraception for the couple. Andrology, 12(7), 1506-1511. https://doi.org/10.1111/andr.13654
Vancouver
Kroopnick JM, Lee MS, Blithe DL. Development of new hormonal male contraception for the couple. Andrology. 2024;12(7):1506-1511. doi:10.1111/andr.13654
BibTeX
@article{Kroopnick2024,
author = {Kroopnick, Jeffrey M and Lee, Min S and Blithe, Diana L},
title = {Development of new hormonal male contraception for the couple},
journal = {Andrology},
year = {2024},
volume = {12},
number = {7},
pages = {1506--1511},
doi = {10.1111/andr.13654}
}
EUVIMED